NuVasive Nabs Nucleus Replacement Device With $43.5 Mil. Pearsalls’ Buy
This article was originally published in The Gray Sheet
Executive Summary
NuVasive expects its cervical nucleus-replacement device to be the first of its kind on the U.S. market in 2010, following its $43.5 mil. purchase of Pearsalls' intellectual property portfolio
You may also be interested in...
NuVasive Boosts Artificial Disc Development, Stock; OTC Index Rises 15%
NuVasive will use profits gained from a series of 510(k)-cleared spinal devices to fuel artificial disc and nucleus replacement development in 2006
NuVasive Boosts Artificial Disc Development, Stock; OTC Index Rises 15%
NuVasive will use profits gained from a series of 510(k)-cleared spinal devices to fuel artificial disc and nucleus replacement development in 2006
NuVasive files IDE
IDE filed for NeoDisc cervical nucleus replacement device, the company announces Oct. 24, increasing the device's odds of being the first of its kind to market. NuVasive acquired NeoDisc from AMI Holding's subsidiary Pearsalls in August. The firm plans to market NeoDisc with its Cerpass cervical total disc replacement, for which it filed an IDE in July. NuVasive expects that NeoDisc could reach the U.S. market in 2010 (1"The Gray Sheet" Aug. 8, 2005, p. 15)...